{
  "docId": "019dd923-5f69-752d-a9b7-cb9ca917cc95",
  "docSlug": "RKx0dsiKeHCYSDIkE7uF",
  "documentTitle": "Cyclica is already using AI to discover new medicines based on psychedelics. Here's the presentation the biotech startup used to raise a fresh $17 million.",
  "authorId": "Pitchdecks",
  "authorName": "Cyclica",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.78,
  "pageNumber": 9,
  "pageCount": 10,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "closing_ask",
  "function": "state_next_steps",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a 'Seeking/From/Offering' structure to frame the investment opportunity.",
  "elementsJson": [
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b7-cb9ca917cc95/9",
  "deckHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95#slide-9",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Seeking: CAD$20M in a Series B round of financing to expand our biotech partnerships and Joint Ventures & pharma deals globally, deliver on R&D roadmap, bolster IP portfolio, and enhance ops.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-a28e-768f-b415-aabe08b19ea1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.85,
        "x": 0.08,
        "y": 0.45
      },
      "kind": "list",
      "text": "From: Investors with a strong understanding of healthcare, life sciences and technology, who share our vision of transforming the discovery of better medicines with a computationally centric approach, and who are dedicated to supporting our commercial and R&D strategy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dfec4d2-7c0c-412f-8a08-7fbfed18f3e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.85,
        "x": 0.08,
        "y": 0.7
      },
      "kind": "list",
      "text": "Offering: An opportunity to invest in a leading neo biotechnology company that is accelerating and improving drug discovery. Our partnership / JV model, together with relationships with big pharma, will usher in a wave of R&D productivity and improve patient’s lives across all disease areas.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa373f94-28e1-4d1c-9d90-e84806a5e7d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "list",
      "text": "Seeking: CAD$20M in a Series B round of financing to expand our biotech partnerships and Joint Ventures & pharma deals globally, deliver on R&D roadmap, bolster IP portfolio, and enhance ops.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c665fe80-8379-4425-9e66-0d7169c8f9f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Series B funding: CAD$20M",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-a28e-768f-b415-ae8501a06acd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.08,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "We have been capital efficient to date as we validated our technologies, platforms and business model. We have achieved our milestones and are primed for global scale and impact.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b03081a-c506-4437-a279-2f311e61fcf7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6deaf774-516a-46da-9cd4-8fce54352f51",
      "evidence": "The document implies that traditional AI in drug discovery companies are limited, and Cyclica's platform offers a more comprehensive solution.",
      "position": 0,
      "objective": "What is the cost of not adopting a more holistic approach to drug discovery?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}